Cardio in Medical Technology

From eResearchTechnology to ERT

...SOP-driven, Project Assurance methodology that delivers exceptional performance metrics and customer satisfaction. Originally founded in 1972 as cardio Data Systems, the company moved its headquarters to Philadelphia in 1993 and following a series of acquisitions formed the company eResearchTechnology...

deCODE Receives California Clinical Laboratory License

...le at http://www.decodeme.com . The full genome Complete Scan scan and the cardio and Cancer scans build on deCODE's global leadership in the discovery of co...agnostics.com ; for our pioneering personal genome analysis service and new cardio and Cancer scans, integrating the genetic variants included in these tests ...

deCODE Breakthrough in Thyroid Cancer May Enable More Targeted Risk Assessment and Earlier Intervention

...at http://www.decode.com ; on our diagnostics site at http://www.decodediagnostics.com ; for our pioneering personal genome analysis service and new cardio and Cancer scans, integrating the genetic variants included in these tests and those linked to another twenty common diseases, at http://www.decodeme...

Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds

...mpany to offer a high- sensitivity C-reactive protein (CRP) test cleared by the U.S. Food and Drug Administration for cardiac risk stratification. The cardio CRP test helps physicians assess the risk a patient may have a heart attack based on CRP levels and other factors. Quest Diagnostics was also one of t...

Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population

...the telmisartan group versus the ramipril group) was 1.01, with a 95 percent CI of 0.94 - 1.09. Telmisartan is now the only ARB to have demonstrated cardio and vascular risk reduction benefits beyond lowering blood pressure in this high-risk population;(1) these benefits may be attributed to the specific ...

GSK and Adolor Announce Preliminary Results from Phase 3 Safety Study of Alvimopan (Entereg/Entrareg)

...l Infarction - (0) 7 (1.30%)2 (0.38%) 1 (0.08%)2 (0.25%) 8 (0.46%) ---------------------------------------------------------------------- All cardio - vascular SAEs 3 (1.12%)14 (2.60%)5 (0.96%)14 (1.18%)8 (1.01%)28 (1.62%) ----------------------------------------------------------------...

Dade Behrings (hsCRP) Tests and BNTM Series Analyzers

...mation level and produces a relative risk assessment, states Gary Samuel, a spokesperson for Quest Diagnostics, who provides Dade Behrings test as its cardio CRP. He adds, It predicts the risk of a cardiovascular event relative to the general population, and provides this data in an easy-to-read format. ...